BRCA1/2-Mutated Breast Cancer in Select EU Markets: Incidence, Treatable Populations, and Potential Market Size for Parp Inhibitors
Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.397
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2017
Authors
Publisher
Elsevier BV